MedTrace Logo

Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer

NCT07041320 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-06-27

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the efficacy and safety of oral metronomic vinorelbine and PD-1 inhibitors in elderly patients with unoperable, locally advanced or metastatic non-small-cell lung cancer. The primary end point was objective response rate (ORR), and the second end points included disease control rate (DCR), progression-free survival (PFS), and safety. Participants over 65 years old, received oral metronomic vinorelbine 40mg every week (20mg for patients over 80 years old), combined with PD-1 inhibitors every 3 weeks.

Conditions

  • Lung Cancer (NSCLC)
  • Elderly (People Aged 65 or More)

Sponsors & Collaborators

  • Anhui Chest Hospital

    lead OTHER

Principal Investigators

  • Qingming Shi, Doctor · Anhui Chest Hosptial

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041320 on ClinicalTrials.gov